Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Dec:244:183-195.
doi: 10.1016/j.ajo.2022.06.024. Epub 2022 Jul 19.

Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis

Virginia Miraldi Utz  1 , Sheila T Angeles-Han  2 , Najima Mwase  3 , Amy Cassedy  4 , Theresa Hennard  3 , Daniel J Lovell  3 , Sarah Lopper  5 , Hermine I Brunner  3 , Eniolami O Dosunmu  5 , Alexei A Grom  1 , Michael Henrickson  3 , Jennifer L Huggins  3 , Robert A Sisk  6 , Tracy V Ting  3 , Adam H Kaufman  6
Affiliations
Clinical Trial

Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis

Virginia Miraldi Utz et al. Am J Ophthalmol. 2022 Dec.

Abstract

Purpose: A significant number of children with noninfectious, chronic anterior uveitis (CAU) fail to respond to conventional therapy; however, successful alternative biologic treatments (ABT) have not been well described. This study aims to review the clinical and treatment characteristics of children with CAU who require ABT.

Design: Retrospective, nonrandomized clinical study.

Methods: Setting: Tertiary center.

Study population: Children with noninfectious CAU.

Observation procedures: Clinical characteristics, uveitis course, complications, and treatment were compared among patients treated with methotrexate (MTX) monotherapy, conventional TNFα inhibitors (cTNFi), and ABT for >3 months.

Main outcome measure: Success of ABT (abatacept, tocilizumab, and/or golimumab) in children failing conventional treatment.

Results: Of the 52 children with CAU, 75% had juvenile idiopathic arthritis. CAU was controlled in 15 children receiving MTX monotherapy, 28 receiving cTNFi, and 9 receiving ABT (n = 1, abatacept; n = 3, tocilizumab; n = 5, golimumab). Patients in the ABT group had a greater number of total ocular complications per person before ABT than those in the control groups (3.4 vs 0.7 [MTX], P < .001, and 1.5 [cTNFi], P < .001, respectively). In all 9 children on ABT, treatment led to control of CAU and topical glucocorticoids tapered to ≤2 drops/d with no new ocular complications.

Conclusions: In this study, alternative biologics (abatacept, golimumab, and tocilizumab) were useful for treating CAU in children who fail MTX and cTNFi therapy. Patients who were controlled on ABT had more disease activity, ocular complications, and anti-cTNFi neutralizing antibodies (before ABT) than those managed with conventional therapy. Larger studies are required to confirm these findings.

Keywords: Pediatric uveitis; anti-biologic antibodies; biologic; childhood uveitis; chronic anterior uveitis; treatment; treatment outcomes.

PubMed Disclaimer

Publication types

MeSH terms